Date | Title | Description | Source |
24.04.2024 | Govt expands committee for drugs, medical devices pricing re... | - | business-s... |
22.04.2024 | Regeneron to Highlight Advances in Genetic Medicine Research... | Oral presentations include updated results from clinical study of otoferlin gene therapy DB-OTO demo... | einpresswi... |
15.04.2024 | Women of Influence: Health Care 2024 – Ileana Hernandez | - | labusiness... |
15.04.2024 | Regeneron Ventures Launches with $500 Million Commitment to ... | - | globenewsw... |
07.04.2024 | Linvoseltamab Pivotal Data Presented at AACR Reinforce High ... | Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administr... | einpresswi... |
25.03.2024 | Defining Leadership in Clinical Trials: Perspectives from Re... | Xtalks Life Science Webinars
To learn what qualities are necessary to navigate the evolving landscap... | prweb.com/... |
15.03.2024 | A 17-year-old took home $250,000 for his award-winning disco... | Science A 17-year-old took home $250,000 for his award-winning discovery in computer 'brains' that c... | businessin... |
13.03.2024 | High School Seniors Win $1.8 Million at Regeneron Science Ta... | $250,000 top award goes to Achyuta Rajaram in the nation’s oldest and most prestigious Science, Tech... | einpresswi... |
12.03.2024 | High School Seniors Win $1.8 Million at Regeneron Science Ta... | - | globenewsw... |
11.03.2024 | CytomX Therapeutics Reports 2023 Financial Results and Provi... | - CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated... | einpresswi... |
25.10.2023 | Prevent Blindness Provides Informational Resources to Profes... | Prevent Blindness has declared November as Diabetes-related Eye Disease Awareness Month to educate p... | prweb.com/... |
28.09.2023 | Health | When you think about your health, don’t forget your... | By Bernard J. Wolfson, KFF Health News
I vividly remember that late Friday afternoon when my eye pre... | dailycamer... |
11.09.2023 | Is Regeneron Stock Fully Valued At $820? | CHINA - 2023/02/15: In this photo illustration, the American biotechnology company Regeneron ... [+]... | forbes.com... |
26.05.2023 | When a blocked nose isn’t just ‘a morning allergy’ | Picture a world where life’s simple pleasures – the aroma of piping hot coffee, the freshness of new... | channelnew... |
21.05.2023 | Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Pre... | /EIN News/ -- Dupixent is the first and only investigational biologic for COPD that has demonstrated... | einpresswi... |
21.05.2023 | Press Release: Dupixent® (dupilumab) late-breaking Phase 3 C... | /EIN News/ -- Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultan... | einpresswi... |
21.05.2023 | Communiqué de presse: Dupixent® (dupilumab) : présentation d... | /EIN News/ -- Dupixent® (dupilumab) : présentation de résultats de phase III de dernière heure dans ... | einpresswi... |
28.03.2023 | Sonoma Bio inks $75M deal with Regeneron to advance cell the... | Sonoma’s therapies harness regulatory T cells (Tregs), shown here in red interacting with another ty... | geekwire.c... |
23.03.2023 | Communiqué de presse: Dupixent® pourrait devenir le premier ... | /EIN News/ -- Dupixent® pourrait devenir le premier médicament biologique contre la bronchopneumopat... | einpresswi... |
23.03.2023 | Press Release: Dupixent® demonstrates potential to become fi... | /EIN News/ -- Dupixent® demonstrates potential to become first biologic to treat COPD by showing sig... | einpresswi... |
21.03.2023 | Communiqué de presse: Dupixent® (dupilumab) : premier et seu... | /EIN News/ -- Dupixent® (dupilumab) : premier et seul médicament ciblé approuvé par la Commission eu... | einpresswi... |
21.03.2023 | Dupixent® (dupilumab) Approved by European Commission as Fir... | /EIN News/ -- Approximately seven times as many patients aged 6 months to 5 years with severe atopic... | einpresswi... |
21.03.2023 | Press Release: Dupixent® (dupilumab) approved by European Co... | /EIN News/ -- Dupixent® (dupilumab) approved by European Commission as first and only targeted medic... | einpresswi... |
18.03.2023 | Dupixent® (dupilumab) Late-Breaking Data at AAD Show Signifi... | /EIN News/ -- More than twice as many patients on Dupixent achieved clear or almost clear skin compa... | einpresswi... |
18.03.2023 | Press Release: Dupixent® (dupilumab) late-breaking data at A... | Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms ... | einpresswi... |
18.03.2023 | Communiqué de presse: Des données de dernière heure sur Dupi... | /EIN News/ -- Des données de dernière heure sur Dupixent® (dupilumab) présentées au Congrès de l’AAD... | einpresswi... |
13.03.2023 | Breakthrough Therapy (BT) Designation Market Product Analysi... | Breakthrough Therapy (BT) Designation Market size is expected to reach USD 183.07 by 2033, from Usd ... | einpresswi... |
24.02.2023 | Libtayo® (cemiplimab) in Combination with Chemotherapy Recei... | Recommendation based on a Phase 3 trial demonstrating superior survival outcomes for Libtayo plus ch... | einpresswi... |
15.12.2022 | Communiqué de presse: Dupixent® (dupilumab) : premier et seu... | /EIN News/ -- Dupixent® (dupilumab) : premier et seul médicament ciblé approuvé par la Commission eu... | einpresswi... |
15.12.2022 | Press Release: Dupixent® (dupilumab) approved by European Co... | /EIN News/ -- Dupixent® (dupilumab) approved by European Commission as the first and only targeted m... | einpresswi... |
27.10.2022 | Prevent Blindness Offers New Educational Resources for Novem... | Prevent Blindness Offers Videos, Fact Sheets, Social Media Graphics and PowerPoint Presentations to ... | einpresswi... |
27.10.2022 | Prevent Blindness Offers New Educational Resources for Novem... | Prevent Blindness offers new, comprehensive resources for November's Diabetes-related Eye Disease Mo... | prweb.com/... |
11.10.2022 | Press Release: Dupixent® (dupilumab) late-breaking Phase 3 d... | Dupixent® (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histo... | globenewsw... |
28.09.2022 | Press Release: Dupixent® (dupilumab) approved by FDA as the ... | Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodulari... | globenewsw... |
28.09.2022 | Press Release: Dupixent® (dupilumab) approved by FDA as the ... | /EIN News/ -- Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for pr... | einpresswi... |
08.09.2022 | Press Release: Dupixent® (dupilumab) late-breaking Phase 3 d... | /EIN News/ -- Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant impro... | einpresswi... |
08.09.2022 | Press Release: Dupixent® (dupilumab) late-breaking Phase 3 d... | Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in sig... | globenewsw... |
05.09.2022 | ESMO Presentations of Libtayo® (cemiplimab), Fianlimab and N... | First-in-class Phase 1 data for two investigational bispecifics in advanced ovarian cancer and advan... | einpresswi... |
05.09.2022 | Press Release: Late-breaking Dupixent® (dupilumab) data at E... | Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for... | globenewsw... |
14.07.2022 | Press Release: Dupixent® (dupilumab) Phase 3 trial shows pos... | Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eos... | globenewsw... |
31.05.2022 | Press Release: FDA accepts Dupixent® (dupilumab) for priorit... | FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis Dupixent woul... | globenewsw... |
20.05.2022 | Press Release: FDA approves Dupixent® (dupilumab) as first t... | FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with... | globenewsw... |
27.04.2022 | Prevent Blindness and Regeneron Unite to Help Save Eyesight ... | Prevent Blindness expands the "Diabetes and the Eyes” program, with support of Regeneron Pharma... | prweb.com/... |
07.04.2022 | Press Release: Dupixent® (dupilumab) approved by European Co... | Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe as... | globenewsw... |
04.04.2022 | Press Release: FDA accepts Dupixent® (dupilumab) for Priorit... | FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosin... | globenewsw... |
26.03.2022 | Press release: Late-breaking Phase 3 data at AAD 2022 show D... | Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and s... | globenewsw... |
26.02.2022 | Late-breaking data at 2022 AAAAI Annual Meeting show Dupixen... | Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved si... | globenewsw... |
26.02.2022 | Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show... | Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly red... | globenewsw... |
18.02.2022 | Update on ongoing Dupixent® (dupilumab) chronic spontaneous ... | Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program In a Phase 3 t... | globenewsw... |
10.02.2022 | FDA accepts Dupixent® (dupilumab) for Priority Review in chi... | FDA accepts Dupixent® (dupilumab) for Priority Review in children aged 6 months to 5 years with mode... | globenewsw... |
07.02.2022 | Regeneron Pharmaceuticals : Annual Report (Form 10-K) | regn-20211231
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mar... | marketscre... |
04.02.2022 | Regeneron Reports Fourth Quarter and Full Year 2021 Financia... | TARRYTOWN, N.Y., Feb. 4, 2022 /PRNewswire/ --
Fourth quarter 2021 revenues increased 104% to $4.95 b... | salamancap... |
31.01.2022 | CHMP recommends approval of Dupixent® (dupilumab) for childr... | CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe asthma... | globenewsw... |
31.01.2022 | CHMP Recommends Approval of Dupixent® (dupilumab) for Childr... | TARRYTOWN, N.Y. and PARIS, Jan. 31, 2022 /PRNewswire/ --
Recommendation based on pivotal trial that ... | marketscre... |
19.01.2022 | FDA Accepts for Review Libtayo® (cemiplimab-rwlc) in Combina... | TARRYTOWN, N.Y., Jan. 19, 2022 /PRNewswire/ --
Regulatory filing recently submitted in the European ... | marketscre... |
23.12.2021 | Regeneron Announces Presentation at the 40th Annual J.P. Mor... | TARRYTOWN, N.Y., Dec. 22, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will w... | marketscre... |
13.12.2021 | Positive Phase 3 Dupixent® (dupilumab) data in children 6 mo... | Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe ... | globenewsw... |
09.12.2021 | New England Journal of Medicine Publishes Positive Phase 3 D... | TARRYTOWN, N.Y. and PARIS, Dec. 8, 2021 /PRNewswire/ --
Dupixent significantly reduced severe asthma... | marketscre... |
08.12.2021 | New England Journal of Medicine Publishes Positive Phase 3 D... | TARRYTOWN, N.Y. and PARIS, Dec. 8, 2021 /PRNewswire/ --
Dupixent significantly reduced severe asthma... | salamancap... |
08.12.2021 | New England Journal of Medicine publishes positive Phase 3 D... | New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children... | globenewsw... |
23.11.2021 | Founder-led biotech is making space for ideas—and diverse le... | Reshma Shetty, Ph.D., didn’t have a million dollars in her pocket when she came out of MIT with a gr... | fiercebiot... |
17.11.2021 | Regeneron Announces Investor Conference Presentations | TARRYTOWN, N.Y., Nov. 16, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will w... | marketscre... |
16.11.2021 | Regeneron Announces Investor Conference Presentations | TARRYTOWN, N.Y., Nov. 16, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will w... | salamancap... |
15.11.2021 | REGENERON ANNOUNCES $3 BILLION SHARE REPURCHASE PROGRAM | TARRYTOWN, N.Y. - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that its Board of Directo... | marketscre... |
13.11.2021 | Regeneron Announces $3 Billion Share Repurchase Program | TARRYTOWN, N.Y., Nov. 12, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today ... | marketscre... |
13.11.2021 | Regeneron Pharmaceuticals, Inc. announces an Equity Buyback ... | Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) announces a share repurchase program. Under the prog... | marketscre... |
12.11.2021 | Regeneron Announces $3 Billion Share Repurchase Program | TARRYTOWN, N.Y., Nov. 12, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today ... | salamancap... |
12.11.2021 | Regeneron Antibody Cocktail Approved by European Commission ... | TARRYTOWN, N.Y., Nov. 12, 2021 /PRNewswire/ --
EC marketing authorization follows approvals in Japan... | salamancap... |
11.11.2021 | CHMP Recommends EU Approval of Regeneron Antibody Cocktail t... | TARRYTOWN, N.Y., Nov. 11, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today ... | salamancap... |
08.11.2021 | New Phase 3 Analyses Show That a Single Dose of REGEN-COV® (... | TARRYTOWN, N.Y., Nov. 8, 2021 /PRNewswire/ --
Single dose of REGEN-COV (1,200 mg subcutaneous) reduc... | salamancap... |
04.11.2021 | Regeneron Presentations at ASH Highlight Expanding Clinical ... | New data for REGN5458 (BCMAxCD3 bispecific antibody) in patients with heavily pre-treated multiple m... | salamancap... |
04.11.2021 | Regeneron Reports Third Quarter 2021 Financial and Operating... | TARRYTOWN, N.Y., Nov. 4, 2021 /PRNewswire/ --
Third quarter 2021 revenues increased 51% to $3.45 bil... | salamancap... |
25.10.2021 | Regeneron Pharmaceuticals : Second Dupixent® (dupilumab) Pha... | TARRYTOWN, N.Y. and PARIS, Oct. 25, 2021 /PRNewswire/ --
Dupixent 300 mg weekly significantly improv... | marketscre... |
25.10.2021 | Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagiti... | Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disea... | globenewsw... |
22.10.2021 | Dupixent® (dupilumab) is the first biologic to significantly... | Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3... | globenewsw... |
21.10.2021 | Regeneron Pharmaceuticals : FDA Expands Approval of Dupixent... | TARRYTOWN, N.Y. and PARIS, Oct. 20, 2021 /PRNewswire/ --
Dupixent is the only biologic medicine to i... | marketscre... |
20.10.2021 | FDA expands approval of Dupixent® (dupilumab) to include chi... | FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-t... | globenewsw... |
20.10.2021 | FDA Expands Approval of Dupixent® (dupilumab) to Include Chi... | TARRYTOWN, N.Y. and PARIS, Oct. 20, 2021 /PRNewswire/ --
Dupixent is the only biologic medicine to i... | salamancap... |
28.09.2021 | Regeneron Pharmaceuticals : FDA Accepts Libtayo® (cemiplimab... | TARRYTOWN, N.Y., Sept. 28, 2021 /PRNewswire/ --
European Union regulatory submission planned by end ... | marketscre... |
24.09.2021 | Regeneron Pharmaceuticals : Welcomes World Health Organizati... | September 23, 2021
Regeneron Welcomes World Health Organization Recommendation for Use of REGEN- COV... | marketscre... |
15.09.2021 | Regeneron Pharmaceuticals : Announces New U.S. Government Ag... | TARRYTOWN, N.Y., Sept. 14, 2021 /PRNewswire/ --
New agreement for 1.4 million doses of REGEN-COV, br... | marketscre... |
08.09.2021 | Regeneron Pharmaceuticals : Announces Investor Conference Pr... | TARRYTOWN, N.Y., Sept. 8, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will w... | marketscre... |
08.09.2021 | Regeneron Announces Investor Conference Presentations | TARRYTOWN, N.Y., Sept. 8, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will w... | salamancap... |
24.08.2021 | Regeneron Announces Encouraging Topline Phase 2 Data of High... | TARRYTOWN, N.Y., Aug. 24, 2021 /PRNewswire/ --
Phase 3 trials in wet AMD and diabetic macular edema ... | salamancap... |
24.08.2021 | Regeneron Pharmaceuticals : Announces Encouraging Topline Ph... | TARRYTOWN, N.Y., Aug. 24, 2021 /PRNewswire/ --
Phase 3 trials in wet AMD and diabetic macular edema ... | marketscre... |
05.08.2021 | Regeneron Pharmaceuticals : Phase 3 Trial of Libtayo® (cemip... | TARRYTOWN, N.Y. and PARIS, Aug. 5, 2021 /PRNewswire/ --
Libtayo combined with chemotherapy increased... | marketscre... |
05.08.2021 | Regeneron Reports Second Quarter 2021 Financial and Operatin... | TARRYTOWN, N.Y., Aug. 5, 2021 /PRNewswire/ --
Second quarter 2021 revenues increased 163% to $5.14 b... | salamancap... |
03.08.2021 | Regeneron Pharmaceuticals : Announces the 2021 Winners of th... | TARRYTOWN, N.Y., Aug. 3, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today a... | marketscre... |
30.07.2021 | Regeneron Pharmaceuticals : FDA Expands Authorized Use of RE... | TARRYTOWN, N.Y., July 30, 2021 /PRNewswire/ --
Expanded authorization enables use of REGEN-COV for p... | marketscre... |
30.07.2021 | FDA Expands Authorized Use of REGEN-COV™ (casirivimab and im... | TARRYTOWN, N.Y., July 30, 2021 /PRNewswire/ --
Expanded authorization enables use of REGEN-COV for p... | salamancap... |
29.07.2021 | Regeneron Pharmaceuticals : Dupixent® (dupilumab) Significan... | TARRYTOWN, N.Y. and PARIS, July 29, 2021 /PRNewswire/ --
Fifth disease in which Dupixent has demonst... | marketscre... |
29.07.2021 | Sanofi : Dupixent® (dupilumab) significantly improved itch a... | Dupixent® (dupilumab) significantly improved itch and hives in patients with chronic spontaneous urt... | marketscre... |
13.07.2021 | Regeneron again backs ISA Pharma's HPV program in $30M fundi... | Regeneron is once again backing ISA Pharmaceuticals' efforts to move a human papillomavirus treatmen... | fiercebiot... |
13.07.2021 | Regeneron again backs ISA Pharma's HPV program in $30M fundi... | Regeneron is once again backing ISA Pharmaceuticals' efforts to move a human papillomavirus treatmen... | fiercebiot... |
28.06.2021 | Dupixent® (dupilumab) SmPC updated with long-term data reinf... | Dupixent® (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile i... | marketscre... |
25.06.2021 | Regeneron Pharmaceuticals : Libtayo® (cemiplimab) Approved b... | TARRYTOWN, N.Y. and PARIS, June 25, 2021 /PRNewswire/ --
Approval based on data from the largest tri... | marketscre... |
25.06.2021 | Regeneron Pharmaceuticals : Libtayo® (cemiplimab) Approved b... | TARRYTOWN, N.Y. and PARIS, June 25, 2021 /PRNewswire/ --
Approval based on a Phase 3 trial demonstra... | marketscre... |
25.05.2021 | REGENERON PHARMACEUTICALS
Regeneron Pharmaceuticals : Annou... | TARRYTOWN, N.Y., May 25, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will we... | marketscre... |
25.05.2021 | Regeneron Announces Investor Conference Presentations | TARRYTOWN, N.Y., May 25, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will we... | salamancap... |
24.05.2021 | REGENERON PHARMACEUTICALS
Regeneron Pharmaceuticals : Libta... | TARRYTOWN, N.Y. and PARIS, May 24, 2021 /PRNewswire/ --
Libtayo recommended for approval in the firs... | marketscre... |